MapLight Therapeutics, Inc.
MapLight Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Planning underway for ZEPHYR-2, the confirmatory Phase 3 trial of ML-007C-MA in schizophrenia, with topline results expected in the second half 2027